A
Aurelius Omlin
Researcher at Kantonsspital St. Gallen
Publications - 149
Citations - 8361
Aurelius Omlin is an academic researcher from Kantonsspital St. Gallen. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 35, co-authored 126 publications receiving 6712 citations. Previous affiliations of Aurelius Omlin include University of Bern & University of St. Gallen.
Papers
More filters
Journal ArticleDOI
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo,Suzanne Carreira,Shahneen Sandhu,Susana Miranda,Helen Mossop,Raquel Perez-Lopez,Daniel Nava Rodrigues,Dan R. Robinson,Aurelius Omlin,Nina Tunariu,Gunther Boysen,Nuria Porta,Penny Flohr,Alexa Gillman,Ines Figueiredo,Claire Paulding,George Seed,Suneil Jain,Christy Ralph,Andrew Protheroe,Syed A. Hussain,Robert Jones,Tony Elliott,Ursula McGovern,Diletta Bianchini,Jane C. Goodall,Zafeiris Zafeiriou,Chris T. Williamson,Roberta Ferraldeschi,Ruth Riisnaes,Bernardette Ebbs,Gemma Fowler,Desamparados Roda,Wei Yuan,Yi-Mi Wu,Xuhong Cao,Rachel Brough,Helen Pemberton,Roger A'Hern,Amanda Swain,Lakshmi P. Kunju,Rosalind A. Eeles,Gerhardt Attard,Christopher J. Lord,Alan Ashworth,Mark A. Rubin,Karen E. Knudsen,Felix Y. Feng,Arul M. Chinnaiyan,Emma Hall,Johann S. de Bono +50 more
TL;DR: Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate.
Journal ArticleDOI
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
Silke Gillessen,Gerhardt Attard,Tomasz M. Beer,Himisha Beltran,Alberto Bossi,Robert G. Bristow,Brett S. Carver,Daniel Castellano,Byung Ha Chung,Noel W. Clarke,Gedske Daugaard,Ian D. Davis,Johann S. de Bono,Rodolfo Borges dos Reis,Charles G. Drake,Ros Eeles,Eleni Efstathiou,Christopher P. Evans,Stefano Fanti,Felix Y. Feng,Karim Fizazi,Mark Frydenberg,Martin E. Gleave,Susan Halabi,Axel Heidenreich,Celestia S. Higano,Nicolas James,Philip W. Kantoff,Pirkko-Liisa Kellokumpu-Lehtinen,Raja B. Khauli,Gero Kramer,Chris Logothetis,Fernando C. Maluf,Alicia K. Morgans,Michael J. Morris,Nicolas Mottet,Vedang Murthy,William Oh,Piet Ost,Anwar R. Padhani,Chris Parker,Colin C. Pritchard,Mack Roach,Mark A. Rubin,Charles J. Ryan,Fred Saad,Oliver Sartor,Howard I. Scher,Avishay Sella,Neal D. Shore,Matthew R. Smith,Howard R. Soule,Cora N. Sternberg,Hiroyoshi Suzuki,Christopher Sweeney,Matthew R. Sydes,Ian F. Tannock,Bertrand Tombal,Riccardo Valdagni,Thomas Wiegel,Aurelius Omlin +60 more
TL;DR: The presented expert voting results can be used for support in areas of management of men with APC where there is no high-level evidence, but individualised treatment decisions should as always be based on all of the data available.
Journal ArticleDOI
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Shahneen Sandhu,Shahneen Sandhu,William R. Schelman,George Wilding,Victor Moreno,Richard D. Baird,Susana Miranda,Lucy Hylands,Ruth Riisnaes,Martin Forster,Aurelius Omlin,Nathan Kreischer,Khin Thway,Heidrun Gevensleben,L. Sun,John W. Loughney,Manash Shankar Chatterjee,Carlo Toniatti,Carlo Toniatti,Christopher L. Carpenter,Robert Iannone,Stan B. Kaye,Johann S. de Bono,Robert M Wenham +23 more
TL;DR: Niraparib (MK4827) as mentioned in this paper is an oral potent, selective PARP-1/PARP-2 inhibitor that induces synthetic lethality in preclinical tumour models with loss of BRCA and PTEN function.
Journal ArticleDOI
Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: Multicohort, open-label phase II KEYNOTE-199 study
Emmanuel S. Antonarakis,Josep M. Piulats,Marine Gross-Goupil,Jeffrey C. Goh,Jeffrey C. Goh,Kristiina Ojamaa,Christopher J. Hoimes,Ulka N. Vaishampayan,Ranaan Berger,Ahmet Sezer,Tuomo Alanko,Ronald de Wit,Chunde Li,Aurelius Omlin,Giuseppe Procopio,Satoshi Fukasawa,Ken-ichi Tabata,Se Hoon Park,Susan Feyerabend,Charles G. Drake,Haiyan Wu,Ping Qiu,Jeri Kim,Christian Heinrich Poehlein,Johann S. de Bono +24 more
TL;DR: Pembrolizumab monotherapy shows antitumor activity with an acceptable safety profile in a subset of patients with RECIST-measurable and bone-predominant mCRPC previously treated with docetaxel and targeted endocrine therapy.
Journal ArticleDOI
Tumor clone dynamics in lethal prostate cancer
Suzanne Carreira,Alessandro Romanel,Jane Goodall,Emily Grist,Emily Grist,Roberta Ferraldeschi,Roberta Ferraldeschi,Susana Miranda,Davide Prandi,David Lorente,David Lorente,Jean-Sebastien Frenel,Carmel Pezaro,Carmel Pezaro,Aurelius Omlin,Aurelius Omlin,Daniel Nava Rodrigues,Penelope Flohr,Nina Tunariu,Nina Tunariu,Johann S. de Bono,Johann S. de Bono,Francesca Demichelis,Francesca Demichelis,Gerhardt Attard,Gerhardt Attard +25 more
TL;DR: A management paradigm requiring sequential monitoring of advanced prostate cancer patients with plasma and tumor biopsies to ensure early discontinuation of agents when they become potential disease drivers is introduced.